On August 27, 2021, the indication for atezolizumab in combination with nab-paclitaxel as treatment for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 was voluntarily withdrawn by the manufacturer. According to the press release announcing the withdrawal, the decision was not related to any changes in either the efficacy or safety associated with atezolizumab but rather to recent changes in the treatment landscape for TNBC. In light of the withdrawal, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer” has been updated in the journal publication as well as in the free SITC CPG mobile app. December 3, 2021
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us